Develops and manufactures cell-based immunotherapies, specifically CAR-T and TCR T-cell therapies. Now — the numbers.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
The stock sits at $0.20. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 2/10.
Against everything we grade, JWCTF lands somewhere in the middle. The grade moves as the numbers move.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, the revenue breakdown.